

Dr. Aaron Ellenbogen Publications

A. Ellenbogen, A. Nicholas, R. Hauser, P. Bhargava, E. Pappert, B. Navia. Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact of Concomitant Antiemetics and Dopamine Agonists on Nausea and Vomiting [abstract]. *Mov Disord.* 2020; 35 (suppl 1).

A. Ellenbogen, A. Corbin, P. Zhao, D. Kegler-Ebo, H. Roberts. CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks [abstract]. *Mov Disord.* 2020; 35 (suppl 1).

D. Jennings, P. LeWitt, D. Kern, I. Goodman, A. Siderowf, O. Omidvar, A. Ellenbogen, J. Aldred, R. Macuica, S. Huntwork-Rodriguez, C. Ho, M. Troyer. Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson’s Disease Patients with and without LRRK2 mutations [abstract]. *Mov Disord.* 2020; 35 (suppl 1).

W. Jost, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, A. Esquenazi. OnabotulinumtoxinA Reduces Disability in Treatment-Naive Adult Patients with Spasticity: Results from the ASPIRE Study [abstract]. *Mov Disord.* 2019; 34 (suppl 2).

W. Ondo, A. Ellenbogen, S. Isaacson, A. Espay, C. Singer, P. Bhargava, M. Worden, D. Blum, B. Navia. Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis [abstract]. *Mov Disord.* 2019; 34 (suppl 2).

A. Esquenazi, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, W. Jost. OnabotulinumtoxinA treatment in adults with spasticity reduces caregiver burden: Results from the ASPIRE study [abstract]. *Mov Disord.* 2019; 34 (suppl 2).

Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, Welch M, Koenig E, David, E, Fox T, Makh, S, Aldred J, Goodman I, Pepinsky B, Liu Y, Graham D, Weihofen A, Cedarbaum JM. Randomized phase I clinical trial of anti- α -synuclein antibody BIIB054. *Mov Disord*, 2019, August, 34: 1154-1163.

Hauser RA, Sutherland D, Madrid JA, Angeles-Rol M, Frucht S, Isaacson SH, Pagan F, Maddux BN, Li G, Tse W, Walter BL, Kumar R, Kremens D, Lew, MF, Ellenbogen, AL, Oguh O, Vasquez A, Kinney W, Lowery M, Resnick M, Huff N, Posner J, Ballman KV, Harvey BE, Mamillari M, Zasloff M, Barbut D. Targeting neurons in the gastrointestinal tract to treat Parkinson's disease. *Clinical Parkinsonism & Related Disorders*, Volume 1, 2019, Pages 2-7.

Hauser RA, Isaacson SH, Ellenbogen AL, Safirstein BE, Truong DD, Komiathy SF, Kegler-Ebo DM, Zhao P, Oh, C. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. *Parkinsonism & Related Disorders*, July 2019, Volume 64, 175 – 180.

Jankovic J, Goodman I, Safirstein B, Marmon T, Schenk D, Koller M, Zago W, Ness D, Griffith S, Grundman M, Soto J, Osrowitzki S, Boess F, Martin-Facklam M, Quinn J, Isaacson S, Omidvar O, Ellenbogen A, Kinney G. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti- α -Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. *JAMA Neurol.* 2018;75(10):1206–1214.

Elble RJ, Ellenbogen AL. Digitizing Tablet and Fahn–Tolosa–Marín Ratings of Archimedes Spirals have Comparable Minimum Detectable Change in Essential Tremor. *Tremor and Other Hyperkinetic Movements.* 2017; 7.

Olanow CW, Stocchi F, Poewe W, Ellenbogen A, Djaldetti R, Rachmilewitz-Minei T, Cohen Y, Oren S, Kieburtz K. Safety, efficacy and tolerability of continuous SC LD/CD (ND0612H) infusion in PD patients with motor fluctuations. 21st International Congress on Parkinson's Disease and Movement Disorders, Vancouver, BC June 4-8, 2017.

J. Jankovic, I. Goodman, B. Safirstein, D. Schenk, G. Kinney, M. Koller, D. Ness, S. Griffith, M. Grundman, J. Soto, S. Ostrowitzki, F. Boess, M. Martin-Facklam, J. Quinn, S. Isaacson, D. Jennings, O. Omidvar, A. Ellenbogen. Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti-Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson's Disease. 21st International Congress on Parkinson's Disease and Movement Disorders, Vancouver, BC June 4-8, 2017.

M. Stacy, V. Biton, J. Aldred, A. Ellenbogen, R. Rubens, N. Modi, A. Mittur, S. Khanna, S. Gupta. Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease: A single-dose study. 21st International Congress on Parkinson's Disease and Movement Disorders, Vancouver, BC June 4-8, 2017.

W. Olanow, A. Ellenbogen, R. Djaldetti, T. Rachmilewitz Minei, Y. Cohen, S. Oren, K. Kieburtz Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD. 21st International Congress on Parkinson's Disease and Movement Disorders, Vancouver, BC June 4-8, 2017.

Tetrud J¹, Nausieda P², Kreitzman D³, Liang GS⁴, Nieves A⁵, Duker AP⁶, Hauser RA⁷, Farbman ES⁸, Ellenbogen A⁹, Hsu A¹⁰, Kell S¹¹, Khanna S¹², Rubens R¹³, Gupta S¹⁴. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. *J Neurol Sci*. 2017 Feb 15;373:116-123.

LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire M, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed M, Kieburtz KD. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. *Mov Disord*. 2016 Sep;31(9):1356-65.

Ellenbogen A, Raines S, Kanen S. Exploratory trial results for Sage-547 in essential tremor. P4.297, Poster Presentation at American Academy of Neurology, Vancouver, BC April 19, 2016.

Ellenbogen A, Hauser R, Modi N, Khanna S, Hsu A, Gupta S. Onset and duration of clinical Effect of IPX066, an extended release formulation of carbidopa-levodopa, in advanced parkinson's disease. 19th Congress of Parkinson's Disease and Movement Disorders, San Diego, CA. June 2015.

Stocchi F, Hsu A, Khanna A, Ellenbogen A Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. *Parkinsonism and Related Disorders* 20 (2014) 1335-1340.

Ellenbogen A, Bardram K, Chang C, Chen P. A phase II double blind, randomized placebo controlled 4 way crossover study to evaluate the safety and efficacy of OC oral solution for sialorrhea in patient with parkinson's disease. Poster presentation, 17th Congress of Parkinson's Disease and Movement Disorder, Sydney Australia. June, 2013.

Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, Tovera J, Hurt J, Bonzo D, Lassauzet ML, Vu A, Cundy KC. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. *Clin Neuropharmacol*. 2012 Jul-Aug;35(4):165-73.

Lewitt PA, Ellenbogen A, Chen D, Lal R, McGuire K, Zomorodi K, Luo W, Huff FJ. Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. *Clin Neuropharmacol.* 2012 May-Jun;35(3):103-10.

Ellenbogen A, Stocchi F, Duker A, Hsu A, Khanna S, Rubens R, Gupta S. Comparison of Single-Dose Motor Effects of IPX066, a Novel Carbidopa-Levodopa (CD-LD) Extended-Release Formulation, to Immediate-Release CD-LD+entacapone (CLE) in Advanced Parkinson's Disease (PD) Patients. *World Congress on Parkinson's Disease and Movement Disorders*, 2012.

Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. *Movement Disorders* 2011 Oct;26(12):2246-52.

Kavanagh ST, Caivano CK, Ondo WG, Becker PM, Bogan RK, Ellenbogen AL, Kushida CA. Gabapentin Enacarbil in Subjects with Primary Restless Legs Syndrome With and Without Severe Sleep Disturbance: Secondary Analyses of Novel Sleep Endpoints from Two Studies. *25th Anniversary Meeting of the Associated Professional Sleep Societies*, 2011.

LeWitt PA, Ellenbogen AL, Chen D, Lal R, McGuire K, Zomorodi K, Luo W, Huff FJ. Actively Transported Levodopa Prodrug XP21279: A Study in Parkinson's Disease Subjects Experiencing Motor Fluctuations. *World Congress on Parkinson's Disease and Movement Disorders*, 2011.

Ellenbogen AL, Thein SG, Winslow DH, Becker PM, Tolson JM, Lassauzet ML, Chen D. A 52-week study of gabapentin enacarbil in restless legs syndrome. *Clinical Neuropharmacology.* 2011 Jan-Feb;34(1):8-16.

Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP045 Study Group. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. *Clin Neuropharmacol.* 2009 Nov-Dec;32(6):311-20.

Addy C, Assaid C, Hreniuk D, Stroh M, Xu Y, Herring WJ, Ellenbogen A, Jinnah HA, Kirby L, Leibowitz MT, Stewart RM, Tarsy D, Tetrud J, Stoch SA, Gottesdiener K, Wagner J. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. *J Clin Pharmacol.* 2009 Jul;49(7):856-64.

Ellenbogen AL, Hauser RA, Omidvar A, Hsu A, O'Connell M, Kell S, Gupta S. Comparative Efficacy and Safety of a Novel Carbidopa-Levodopa Product (IPX066) and Sinemet in Advanced Parkinson's Disease. *World Parkinson's Congress*, 2009.

Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP052 Study Group. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. *Neurology.* 2009 Feb 3;72(5):439-46.

Ellenbogen, Kushida, Becker, Walters, and Canafax. XP13512 improves RLS symptoms: results of two-phase II clinical studies. *Movement Disorders Society*, 2006.

For more information about clinical trials contact us at:

Research@MindOnline.com